277 related articles for article (PubMed ID: 8608877)
21. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.
Modigliani R; Mary JY; Simon JF; Cortot A; Soule JC; Gendre JP; Rene E
Gastroenterology; 1990 Apr; 98(4):811-8. PubMed ID: 2179031
[TBL] [Abstract][Full Text] [Related]
22. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
Feagan BG; Sandborn WJ
Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
[TBL] [Abstract][Full Text] [Related]
23. Review article: maintenance treatment of Crohn's disease.
Biancone L; Tosti C; Fina D; Fantini M; De Nigris F; Geremia A; Pallone F
Aliment Pharmacol Ther; 2003 Jun; 17 Suppl 2():31-7. PubMed ID: 12786610
[TBL] [Abstract][Full Text] [Related]
24. Budesonide for induction of remission in Crohn's disease.
Otley A; Steinhart AH
Cochrane Database Syst Rev; 2005 Oct; (4):CD000296. PubMed ID: 16235274
[TBL] [Abstract][Full Text] [Related]
25. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group.
Brignola C; Cottone M; Pera A; Ardizzone S; Scribano ML; De Franchis R; D'Arienzo A; D'Albasio G; Pennestri D
Gastroenterology; 1995 Feb; 108(2):345-9. PubMed ID: 7835575
[TBL] [Abstract][Full Text] [Related]
26. Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study.
Mahmud N; Kamm MA; Dupas JL; Jewell DP; O'Morain CA; Weir DG; Kelleher D
Gut; 2001 Oct; 49(4):552-6. PubMed ID: 11559654
[TBL] [Abstract][Full Text] [Related]
27. Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease.
de Franchis R; Omodei P; Ranzi T; Brignola C; Rocca R; Prada A; Pera A; Vecchi M; Del Piano M; Ferrara A; Belloli C; Piodi L; Framarin L; Astegiano M; Riccioli FA; Meucci G
Aliment Pharmacol Ther; 1997 Oct; 11(5):845-52. PubMed ID: 9354191
[TBL] [Abstract][Full Text] [Related]
28. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials.
Hanauer SB; Strömberg U
Clin Gastroenterol Hepatol; 2004 May; 2(5):379-88. PubMed ID: 15118975
[TBL] [Abstract][Full Text] [Related]
29. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease.
McLeod RS; Wolff BG; Steinhart AH; Carryer PW; O'Rourke K; Andrews DF; Blair JE; Cangemi JR; Cohen Z; Cullen JB
Gastroenterology; 1995 Aug; 109(2):404-13. PubMed ID: 7615189
[TBL] [Abstract][Full Text] [Related]
30. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group).
Lorenz-Meyer H; Bauer P; Nicolay C; Schulz B; Purrmann J; Fleig WE; Scheurlen C; Koop I; Pudel V; Carr L
Scand J Gastroenterol; 1996 Aug; 31(8):778-85. PubMed ID: 8858747
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group.
Miner P; Hanauer S; Robinson M; Schwartz J; Arora S
Dig Dis Sci; 1995 Feb; 40(2):296-304. PubMed ID: 7851193
[TBL] [Abstract][Full Text] [Related]
32. A controlled double blind study of azathioprine in the management of Crohn's disease.
Candy S; Wright J; Gerber M; Adams G; Gerig M; Goodman R
Gut; 1995 Nov; 37(5):674-8. PubMed ID: 8549944
[TBL] [Abstract][Full Text] [Related]
33. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease.
Small RE; Schraa CC
Pharmacotherapy; 1994; 14(4):385-98. PubMed ID: 7937276
[TBL] [Abstract][Full Text] [Related]
34. Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis.
Schreiber S; Howaldt S; Raedler A
Gut; 1994 Aug; 35(8):1081-5. PubMed ID: 7926910
[TBL] [Abstract][Full Text] [Related]
35. Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease.
Singleton JW; Hanauer S; Robinson M
Dig Dis Sci; 1995 May; 40(5):931-5. PubMed ID: 7729281
[TBL] [Abstract][Full Text] [Related]
36. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial.
Hanauer SB; Korelitz BI; Rutgeerts P; Peppercorn MA; Thisted RA; Cohen RD; Present DH
Gastroenterology; 2004 Sep; 127(3):723-9. PubMed ID: 15362027
[TBL] [Abstract][Full Text] [Related]
37. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease.
Cortot A; Colombel JF; Rutgeerts P; Lauritsen K; Malchow H; Hämling J; Winter T; Van Gossum A ; Persson T; Pettersson E
Gut; 2001 Feb; 48(2):186-90. PubMed ID: 11156638
[TBL] [Abstract][Full Text] [Related]
38. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.
Coward S; Kuenzig ME; Hazlewood G; Clement F; McBrien K; Holmes R; Panaccione R; Ghosh S; Seow CH; Rezaie A; Kaplan GG
Inflamm Bowel Dis; 2017 Mar; 23(3):461-472. PubMed ID: 28146003
[TBL] [Abstract][Full Text] [Related]
39. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.
Tromm A; Bunganič I; Tomsová E; Tulassay Z; Lukáš M; Kykal J; Bátovský M; Fixa B; Gabalec L; Safadi R; Kramm HJ; Altorjay I; Löhr H; Koutroubakis I; Bar-Meir S; Stimac D; Schäffeler E; Glasmacher C; Dilger K; Mohrbacher R; Greinwald R;
Gastroenterology; 2011 Feb; 140(2):425-434.e1; quiz e13-4. PubMed ID: 21070781
[TBL] [Abstract][Full Text] [Related]
40. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.
Louis E; Mary JY; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Dupas JL; Pillant H; Picon L; Veyrac M; Flamant M; Savoye G; Jian R; Devos M; Porcher R; Paintaud G; Piver E; Colombel JF; Lemann M;
Gastroenterology; 2012 Jan; 142(1):63-70.e5; quiz e31. PubMed ID: 21945953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
